NCT07257562 Combined Use of Bacteroides Fragilis and BCAAs on HBsAg Clearance
| NCT ID | NCT07257562 |
| Status | Recruiting |
| Phase | — |
| Sponsor | First Affiliated Hospital of Fujian Medical University |
| Condition | Chronic Hepatitis B |
| Study Type | OBSERVATIONAL |
| Enrollment | 40 participants |
| Start Date | 2025-06-01 |
| Primary Completion | 2026-03-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 40 participants in total. It began in 2025-06-01 with a primary completion date of 2026-03-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this prospective observational study is to determine the effects of concomitant administration of Bacteroides fragilis and Branched-Chain Amino Acids on hepatitis B virus clearance. The primary question it aims to answer is whether this concomitant administration can promote HBV clearance. The study will observe the HBV clearance rate in chronic hepatitis B patients who receive Bacteroides fragilis and BCAA as a supplement to their routine antiviral therapy. For comparison, researchers will compare the clearance rate in this group to that observed in a control group of chronic hepatitis B patients receiving a standard antiviral regimen based on PegIFNα2b and nucleoside analogs.
Eligibility Criteria
Inclusion Criteria: \- chronic hepatitis B patients Exclusion Criteria: * patients with malignancies * patients with other liver diseases * pregnancy patients
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07257562 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Chronic Hepatitis B. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07257562 currently recruiting?
Yes, NCT07257562 is actively recruiting participants. Contact the research team at zdy20221021@gmail.com for enrollment information.
Where is the NCT07257562 trial being conducted?
This trial is being conducted at Fuzhou, China.
Who is sponsoring the NCT07257562 clinical trial?
NCT07257562 is sponsored by First Affiliated Hospital of Fujian Medical University. The trial plans to enroll 40 participants.